ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1764

Disease Modifying Anti-rheumatic Drug and Biologic Therapy in Pregnancy: A Single-center Mixed Methods Study
Abstract Number: 1765

Obstetric Outcomes in Younger Women Less Than 21 Years of Age Compared to Women Between Age 21 and 25 Years with Rheumatic Disease
Abstract Number: 1766

Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Lupus Erythematosus Patients
Abstract Number: 1767

Maternal Peripartum Outcomes Are Similar to the General Population in Rheumatoid Arthritis Pregnancies
Abstract Number: 1768

The Importance of Pregnancy Planning in Lupus Pregnancies
Abstract Number: 1769

Patient-reported COVID-19 Infection in Pregnant Women with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance Patient Experience Survey
Abstract Number: 1770

Lupus Low Disease Activity State Protects Against Pre-Term Birth
Abstract Number: 1771

Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Review and Meta-analysis
Abstract Number: 1772

Vaccinations of Infants Born to Mothers on TNF Inhibitors: Safe Administration of Live-vaccines Given Per the National Immunization Program
Abstract Number: 1773

Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
Abstract Number: 1774

Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study
Abstract Number: 1775

Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies
Abstract Number: 1776

Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in Women with Systemic Lupus Erythematosus
Abstract Number: 1777

Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Abstract Number: 1778

Improving Teratogenic Medication Consent and Sexual Activity Screening in Adolescent and Young Females: A Pediatric Rheumatology Reproductive Health Initiative

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].